ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.740
+0.170 (10.83%)
At close: Jan 30, 2026, 4:00 PM EST
1.710
-0.030 (-1.72%)
After-hours: Jan 30, 2026, 7:58 PM EST
ALX Oncology Holdings Employees
ALX Oncology Holdings had 44 employees as of September 30, 2025. The number of employees decreased by 45 or -50.56% compared to the same quarter last year.
Employees
44
Change
-45
Growth
-50.56%
Revenue / Employee
n/a
Profits / Employee
-$2,454,773
Market Cap
94.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 44 | -45 | -50.56% |
| Jun 30, 2025 | 49 | -32 | -39.51% |
| Mar 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Sep 30, 2024 | 89 | 18 | 25.35% |
| Jun 30, 2024 | 81 | 9 | 12.50% |
| Mar 31, 2024 | 74 | 9 | 13.85% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Sep 30, 2023 | 71 | 16 | 29.09% |
| Jun 30, 2023 | 72 | 20 | 38.46% |
| Mar 31, 2023 | 65 | 21 | 47.73% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Sep 30, 2022 | 55 | 23 | 71.88% |
| Jun 30, 2022 | 52 | 23 | 79.31% |
| Mar 31, 2022 | 44 | 20 | 83.33% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Sep 30, 2021 | 32 | 15 | 88.24% |
| Jun 30, 2021 | 29 | 10 | 52.63% |
| Mar 31, 2021 | 24 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Artiva Biotherapeutics | 106 |
| Fortress Biotech | 101 |
| Precision BioSciences | 67 |
| Pyxis Oncology | 44 |
| Cassava Sciences | 30 |
| Cognition Therapeutics | 28 |
| MAIA Biotechnology | 13 |
ALXO News
- 1 day ago - ALX Oncology Announces Pricing of Underwritten Offering - GlobeNewsWire
- 1 day ago - New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - GlobeNewsWire
- 16 days ago - ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - GlobeNewsWire
- 7 weeks ago - ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - GlobeNewsWire
- 2 months ago - ALX Oncology to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript - Seeking Alpha